Melanoma Study Achieves Key Milestone as Bristol's Flagship Treatment Secures Improvement in Survival Rates

  • Bristol Myers Squibb & Co BMY announced results from the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) in melanoma patients.
  • Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo.
  • Related: Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis. 
  • No new safety signals were observed at the time of the analysis.
  • CheckMate -76K is part of BMS' development program studying Opdivo and Opdivo-based combinations in earlier stages of cancer, which currently spans seven tumor types.
  • The company will complete a full evaluation of the CheckMate -76K data and looks forward to sharing the results at an upcoming medical conference.
  • Price Action: BMY shares are up 1.37% at $71.44 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!